期刊文献+

吡格列酮对2型糖尿病伴发肥胖症患者的疗效 被引量:1

下载PDF
导出
出处 《国外医学(老年医学分册)》 2009年第1期44-44,共1页 Foreign Medical Sciences(Geriatrics)
  • 相关文献

同被引文献8

  • 1Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes[J]. Diabetes Obes Metab, 1999, 1 (supp Ⅱ ) :1-7.
  • 2Berg AH,Combs TP,Dux,et al. The alipocyte-secrects protein Acrp 30 enhances hepatic Insulin action[J]. Nat Med,2001,7(8) :947.
  • 3Bailey CJ,Green BD,Flatt PR. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone [J]. Expert Opin Investig Drugs, 2010,19(8) : 1 017- 1 025.
  • 4Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism[J]. Diabetes Obes Metab, 2007,9 (5) :640-647.
  • 5Lebovitz HE, Dole JF, Patwardham R, et al. Rosiglitazone menotherapy is effective in patients with type 2 diabetes [J]. J Clin Endocrinol Metab, 2002, 86: 280- 288.
  • 6Forman LM,Simmons DA,Diamond RH. Hepatic fail- ure in a patient taking rosiglitazone [J]. Ann Intern Med,2000,17:287.
  • 7AI Saman J,Arjimand H,Kemp DG,et al. Hepatocellular injury in a patient rceiving rosiglitazone[J]. Ann Intern Med,2000,132:121.
  • 8傅晓莹,邓海鸥,杨华章.盐酸吡格列酮治疗2型糖尿病患者的有效性和安全性研究[J].实用医学杂志,2010,26(3):451-453. 被引量:15

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部